176 related articles for article (PubMed ID: 20397181)
21. Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.
Poplawski SE; Lai JH; Sanford DG; Sudmeier JL; Wu W; Bachovchin WW
J Med Chem; 2011 Apr; 54(7):2022-8. PubMed ID: 21388136
[TBL] [Abstract][Full Text] [Related]
22. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
[TBL] [Abstract][Full Text] [Related]
23. Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV.
Bower AM; Real Hernandez LM; Berhow MA; de Mejia EG
J Agric Food Chem; 2014 Jul; 62(26):6147-58. PubMed ID: 24881464
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
[TBL] [Abstract][Full Text] [Related]
25. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
Al-masri IM; Mohammad MK; Tahaa MO
J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1061-6. PubMed ID: 19640223
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
[TBL] [Abstract][Full Text] [Related]
28. Recovery, viscoelastic and functional properties of Barbel skin gelatine: investigation of anti-DPP-IV and anti-prolyl endopeptidase activities of generated gelatine polypeptides.
Sila A; Martinez-Alvarez O; Haddar A; Gómez-Guillén MC; Nasri M; Montero MP; Bougatef A
Food Chem; 2015 Feb; 168():478-86. PubMed ID: 25172738
[TBL] [Abstract][Full Text] [Related]
29. Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).
Paliwal S; Seth D; Yadav D; Yadav R; Paliwal S
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):129-40. PubMed ID: 21299434
[TBL] [Abstract][Full Text] [Related]
30. A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors.
Hu CX; Huang H; Zhang L; Huang Y; Shen ZF; Cheng KD; Du GH; Zhu P
Biotechnol Lett; 2009 Jul; 31(7):979-84. PubMed ID: 19267232
[TBL] [Abstract][Full Text] [Related]
31. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
[TBL] [Abstract][Full Text] [Related]
32. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.
Matheeussen V; Baerts L; De Meyer G; De Keulenaer G; Van der Veken P; Augustyns K; Dubois V; Scharpé S; De Meester I
Biol Chem; 2011 Mar; 392(3):189-98. PubMed ID: 21194356
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
Tran T; Quan C; Edosada CY; Mayeda M; Wiesmann C; Sutherlin D; Wolf BB
Bioorg Med Chem Lett; 2007 Mar; 17(5):1438-42. PubMed ID: 17174090
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
Racys DT; Rea D; Fülöp V; Wills M
Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
[TBL] [Abstract][Full Text] [Related]
37. Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors.
Li-Chan EC; Hunag SL; Jao CL; Ho KP; Hsu KC
J Agric Food Chem; 2012 Feb; 60(4):973-8. PubMed ID: 22225496
[TBL] [Abstract][Full Text] [Related]
38. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.
Miyamoto Y; Banno Y; Yamashita T; Fujimoto T; Oi S; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Amano M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Jan; 19(1):172-85. PubMed ID: 21163664
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.
Wu D; Jin F; Lu W; Zhu J; Li C; Wang W; Tang Y; Jiang H; Huang J; Liu G; Li J
Chem Biol Drug Des; 2012 Jun; 79(6):897-906. PubMed ID: 22381062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
